Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 08, 2022 08:00 ET | Source: Eyenovia, Inc.

Eyenovia Concludes Type A Meeting with FDA Related to MydCombi™ NDA Resubmission

NEW YORK, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today...
February 07, 2022 08:30 ET | Source: Eyenovia, Inc.

Eyenovia Announces Changes to Board of Directors

NEW YORK, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today...
November 10, 2021 16:05 ET | Source: Eyenovia, Inc.

Eyenovia Reports Third Quarter 2021 Financial Results

On track with VISION-2 phase 3 presbyopia trial and expedited resubmission of MydCombi™ New Drug Application as a drug/device combination in early 2022 Current cash resources anticipated to be...
November 08, 2021 08:00 ET | Source: Eyenovia, Inc.

Eyenovia to Participate in Myopia Panel Discussion at the Eyecelerator@AAO 2021 Meeting

NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array...
November 05, 2021 15:25 ET | Source: Eyenovia, Inc.

CORRECTING AND REPLACING: Eyenovia to Report Third Quarter 2021 Results on Wednesday, November 10

Eyenovia will release third quarter 2021 results on Wednesday, November 10, after the close. The prior version of this press release incorrectly stated that third quarter 2021 results would be...
November 04, 2021 16:05 ET | Source: Eyenovia, Inc.

Eyenovia to Report Third Quarter 2021 Results on Thursday, November 11

NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics,...
November 04, 2021 08:00 ET | Source: Eyenovia, Inc.

Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia

Vision-2 follows successful Vision-1 trial with expected top-line results in Q2 2022 Presbyopia represents a multi-billion-dollar market opportunity in the U.S. alone NEW YORK, Nov. 04, 2021 ...
October 25, 2021 08:00 ET | Source: Eyenovia, Inc.

Eyenovia Announces Reclassification of MydCombi(tm) as Drug-Device Combination Product by FDA

Genus Medical Technologies, LLC v. FDA legal case leads to agency-wide review and reclassification of eye cups, eye droppers, and ophthalmic dispensers Company received Complete Response Letter...
August 11, 2021 16:05 ET | Source: Eyenovia, Inc.

Eyenovia Reports Second Quarter 2021 Financial Results

Announced positive topline data from its Phase 3 VISION-1 study evaluating MicroLine for the treatment of presbyopia Company on track to initiate second Phase 3 presbyopia trial, VISION-2, by...
August 04, 2021 08:00 ET | Source: Eyenovia, Inc.

Eyenovia to Report Second Quarter 2021 Results on Wednesday, August 11

NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array...